PDF herunterladen
Nervenheilkunde 2008; 27(08): 709-716
DOI: 10.1055/s-0038-1627132
Originaler Artikel
Schattauer GmbH

Halluzinationen und Psychose bei der Parkinson-Erkrankung

Konsequenzen für diagnostisches und therapeutisches HandelnHallucinations and psychosis in Parkinson’s diseaseConsequences for diagnosis and management
G. Ebersbach
1   Neurologisches Fachkrankenhaus für Bewegungsstörungen /Parkinson, Beelitz-Heilstätten
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Eingegangen am: 22. April 2008

angenommen am: 28. April 2008

Publikationsdatum:
22. Januar 2018 (online)

    Lizenzen und Reprints

Zusammenfassung

Psychotische Symptome sind eine häufige Komplikation der Parkinson-Erkrankung und treten oft im Zusammenhang mit der Parkinson-Demenz und der Demenz mit Lewy- Körperchen auf. Da Halluzinationen bei Parkinson-Syndromen ohne Lewy-Körperchen wie der Multisystematrophie oder der progressiven Blickparese selten vorkommen, hat das Auftreten von Halluzination auch eine Wertigkeit für die Differenzialdiagnose.

Präsenzgefühle, illusionäre Verkennungen und visuelle Pseudohalluzinationen mit erhaltener Einsicht werden zunächst von vielen Betroffenen als wenig belastend erlebt. Da derartige „benigne“ Wahrnehmungsstörungen bei der Parkinson-Erkrankung allerdings mit einer hohen Inzidenz schwerer psychotischer Störungen im weiteren Krankheitsverlauf assoziiert sind, sollte frühzeitig eine medikamentöse Therapie in Betracht gezogen werden. Neben Clozapin können in Abhängigkeit von den Begleitumständen auch Quetiapin, Benzodiazepine und Cholinesterase-Inhibitoren zur Behandlung von Halluzinationen in Frage kommen.

Summary

Psychotic symptoms are a frequent complication of Parkinson’s disease. Parkinson’s disease dementia and dementia with Lewy bodies are conditions with increased incidence of psychosis. Occurrence of hallucinations has certain diagnostic implications since hallucinations are only rarely reported in parkinsonian syndromes without Lewy bodies such as multi-system atrophy or progressive supranuclear palsy. Feelings of presence or passage, visual illusions and pseudo-hallucinations with retained insight are often experienced without causing major distress to the patient. Yet, since these “benign” hallucinations bear a high-risk of transition to severe psychosis medical treatment should also be considered in early stages. In addition to clozapine quetiapine, benzodiazepines and central inhibitors of cholinesterase can be of value in some circumstances.

Schlüsselwörter

Parkinson-Syndrom - Clozapin - Psychose - Halluzinationen - Dopaminergika

Keywords

Parkinson’s disease - clozapine - psychosis - hallucinations - dopaminergics
 

  • Literatur

  • 1 Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56 (Suppl. 05) 595-601.
    CrossrefGoogle Scholar
  • 2 Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriatr Psychiatry 2001; 16 (Suppl. 05) 528-536.
    CrossrefGoogle Scholar
  • 3 Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology 2000; 55 (Suppl. 02) 281-288.
    CrossrefGoogle Scholar
  • 4 Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001; 70 (Suppl. 06) 727-733.
    CrossrefGoogle Scholar
  • 5 de Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord 2005; 20 (Suppl. 02) 212-217.
    CrossrefGoogle Scholar
  • 6 Dewey Jr RB, O’Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson’s disease. Neurology 2000; 55 (Suppl. 11) 1753-1754.
    CrossrefGoogle Scholar
  • 7 Diener HC. Leitlinien für Diagnostik und Therapie in der Neurologie. 2005. Stuttgart, Thieme. Ebersbach G. An artist’s view of drug-induced hallucinosis. Mov Disord 2003; 18 (Suppl. 07) 833-834.
    CrossrefGoogle Scholar
  • 8 Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van LT, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351 (Suppl. 24) 2509-2518.
    CrossrefGoogle Scholar
  • 9 Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, Lees AJ. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19 (Suppl. 04) 397-405.
    CrossrefGoogle Scholar
  • 10 Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24 (Suppl. 05) 295-299.
    CrossrefGoogle Scholar
  • 11 Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R. Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 2003; 60 (Suppl. 11) 1756-1761.
    CrossrefGoogle Scholar
  • 12 Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123 Pt 4 733-745.
    CrossrefGoogle Scholar
  • 13 Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson’s disease. Acta Neurol Scand 1991; 84 (Suppl. 02) 111-113.
    CrossrefGoogle Scholar
  • 14 Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005; 64 (Suppl. 01) 81-86.
    CrossrefGoogle Scholar
  • 15 Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006; 66 (Suppl. 09) 1427-1429.
    CrossrefGoogle Scholar
  • 16 Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of ,,benign hallucinations“ in Parkinson disease. Arch Neurol 2006; 63 (Suppl. 05) 713-716.
    CrossrefGoogle Scholar
  • 17 Koller W, Lees A, Doder M, Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov Disord 2001; 16 (Suppl. 05) 858-866.
    CrossrefGoogle Scholar
  • 18 Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68 (Suppl. 17) 1356-1363.
    CrossrefGoogle Scholar
  • 19 Lorberboym M. et al. [123]-FP-CIT SPECTimaging for distinguishing drug-induced parkinsonism from Parkinson’s Disease. Mov Disord 2006; 21 (Suppl. 04) 510-514.
    CrossrefGoogle Scholar
  • 20 McKeith I, Del ST, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356 9247 2031-2036.
    CrossrefGoogle Scholar
  • 21 McKeith IG. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (Suppl. 12) 1863-1872.
    CrossrefGoogle Scholar
  • 22 Moskovitz C, Moses III H, Klawans HL. Levodopa- induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; June 135 (Suppl. 06) 669-675.
    CrossrefGoogle Scholar
  • 23 Nebe A, Ebersbach G. Selective diplopia in Parkinson’s disease: a special subtype of visual hallucination?. Mov Disord 2007; 22 (Suppl. 08) 1175-1178.
    CrossrefGoogle Scholar
  • 24 Onofrj M, Thomas A, Iacono D, Di IA, Bonanni L. Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients. Eur Neurol 2001; 46 (Suppl. 01) 11-16.
    Google Scholar
  • 25 Poewe W. Psychosis in Parkinson’s disease. Mov Disord 2003; 18 (Suppl. 06) S80-S87.
    CrossrefGoogle Scholar
  • 26 Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 2007; 22 (Suppl. 03) 313-318.
    CrossrefGoogle Scholar
  • 27 Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22 (Suppl. 08) 1061-1068.
    CrossrefGoogle Scholar
  • 28 Riedel O, Dodel R, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Wittchen H-U.. Wie beurteilen Ärzte die Häufigkeit demenzieller, depressiver und psychotischer Symptome bei Patienten mit der Parkinson-Krankheit?. Aktuelle Neurologie 2006; 33: 374-380.
    Artikel in Thieme ConnectGoogle Scholar
  • 29 Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology 1993; 43 12 Suppl 6 S47-S52.
    Google Scholar
  • 30 The French Clozapine Parkinsin Study Group.. Clozapine in drug-induced psychosis in Parkinson’s disease. The French Clozapine Parkinson Study Group. Lancet 1999; 353 9169 2041-2042.
    CrossrefGoogle Scholar
  • 31 The Parkinson Study Group.. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1999; 340 (Suppl. 10) 757-763.
    CrossrefGoogle Scholar
  • 32 Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical Parkinsonism. J Neurol Neurosrg Psychiatry. 2007 published online 2007; doi:10.1136/jmmp.2007.124677
    Google Scholar
  • 33 Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 2007; 4 (Suppl. 10) 5-10.
    Google Scholar